Testing: The Gallium Scan

A gallium scan uses a radioactive compound called gallium citrate to detect and image inflammation in the body. The gallium citrate acts as a radiotracer, a compound that attaches to specific cells or tissues in the body and emits radiation. These beams are then picked up by a scanner which maps their origin.

In a gallium scan, the radiotracer attaches to white blood cells (WBCs) and tumor cells. Since WBCs collect in areas of inflammation, the gallium locates to damaged areas in the body. This damage can indicate tumor metastasis, or it can result from chemotherapy or radiation. For this reason, gallium scans can help locate tumors in lymphomas as well as monitor the effectiveness of treatment protocols.

The process begins when a patient is injected with the gallium citrate. About two days later, the patient will report back to the health care facility for the actual scan. This time lapse allows the gallium to spread throughout the body to all areas of inflammation.

This scan is not suited for pregnant women or anyone who has had a recent scan or X-ray with barium contrast. If you are breast-feeding, the doctor will provide you with instructions on how to best care for your baby during this time. Because gallium stays in the body for several days, you cannot breastfeed during the scan. Oftentimes, mothers must wait four weeks before resuming breast-feeding.

Some patients will also need to receive an enema prior to scanning. The intestines remove gallium from the system; an enema prevents false positives.

Why a Gallium Scan?

The gallium scan is capable of identifying inflammation, which other scans cannot do.

Learn More About Similar Tests

Photo of Gallium Crystals by G. Patton

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap